Cardinal Health, Inc. (CAH)

On our desk, CAH is trading at a record high of $258 after an impressive Q4 earnings beat and a massive lift in fiscal 2027 guidance. Even though total sales of $63.7 billion slightly missed consensus expectations, the top-line shortfall was completely overshadowed by robust profitability metrics and double-digit projected EPS growth of 13% to 15%. Management also approved an incremental $5.0 billion share repurchase authorization on top of completing $1.4 billion in buybacks for fiscal 2026. The stock's 150% rally over the last three years shows strong momentum, and the post-earnings setup remains highly compelling for institutional accumulation.

Analyzing the cash generation profile, CAH delivered stellar performance with $5.2 billion in operating cash flow and $5.0 billion in adjusted free cash flow for full fiscal year 2026. This massive liquidity buffer directly supports their aggressive capital allocation strategy, including the newly approved $5.0 billion share repurchase authorization and the completion of the recent $350 million incremental buyback. The balance sheet strength provides plenty of flexibility to absorb minor product recalls while returning substantial capital to shareholders.

From a risk management standpoint, we are keeping a close eye on the recent Class II recalls of subpotent levothyroxine tablets distributed nationwide in the US alongside the incoming transition of Anita Zielinski as Chief Accounting Officer in November. While these routine distribution and executive shifts rarely derail a Dividend Aristocrat long-term, they introduce operational noise into the compliance profile right as the company integrates its simplified organizational structure. We are tracking whether these supply chain hiccups could impact upcoming gross margin sustainability.

In our clinic, the demand trajectory for specialty products and GLP-1 therapies remains fiercely resilient. Cardinal Health's Pharmaceutical and Specialty Solutions segment posted a 6% revenue increase to $58.8 billion, backed by a significant 500-basis-point tailwind specifically from GLP-1 growth. Upstream and downstream specialty strengths expanded by over 25%, indicating that underlying patient volume and brand sales are holding up exceptionally well across major medical distribution channels heading into fiscal 2027.

Looking at segment performance as a healthcare equity researcher, the Pharmaceutical and Specialty Solutions segment profit jumped 21% to $645 million. This was driven by robust generics program performance alongside brand and specialty portfolio growth. Meanwhile, the Global Medical Products and Distribution segment is leveraging underlying operational improvements alongside the IEEPA tariff refund tailwinds. Management's guidance for fiscal 2027 non-GAAP earnings of $12.40 to $12.60 per share signals high confidence in sustaining these operating margins.

Valuation on Cardinal Health, Inc. (CAH) is elevated relative to historical multiples, but institutional order flow remains supportive. Waiting for a better entry point during broader market volatility.